You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity

    SBC: IMMURX LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): We have discovered, characterized and functionally defined a novel, immune inhibitory ligand. This ligand is hematopoietically-expressed, a distant member of the B7 Ig-superfamily, and its extracellular domain bears homology to the B7 family ligand PD-L1. This molecule is designated as V-domain Immunoglobulin Suppressor of T cell Activation (VISTA). Distinct fr ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. A Rapid Point-of-care Diagnostic for Neisseria gonorrhoeae STDs

    SBC: NetBio, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Improved diagnosis of Neisseria gonorrhoeae (GC) infections represents a critical unmet medical need. The CDC estimates that approximately 700,000 people are infected by GC annually, with approximately half of these cases reported. The clinical spectrum of GC infection includes urethritis and cervicitis, pelvic inflammatory disease (PID), and disseminated disea ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Multi-view, Photon Counting DXA Scanner for Quantitative Musculoskeletal Imaging

    SBC: QUANTUM MEDICAL METRICS, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): The fragility of osteoporotic bones is largely due to alterations in the underlying structural geometry. Research has demonstrated that it is possible to measure the mechanical geometry of human bones in vivo using dualenergy x-ray absorptiometry (DXA) scans. However DXA scanners are designed to measure bone mineral density (BMD) and not structural geometry. Th ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Tissue Scaffold of High Strength and Porosity

    SBC: BIO2 TECHNOLOGIES, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): According to the Center of Disease Control and Prevention, arthritis is the greatest single cause of chronic pain and disability among Americans .2,3 Currently there is no cure for osteoarthritis, only medication and surgical procedures are available to alleviate the pain and discomfort associated with this degenerative bone disease. Current surgical treatment ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Targeting host response to DAMP for therapy of Rheumatoid Arthritis

    SBC: Oncoimmune Inc            Topic: NIAMS

    DESCRIPTION (provided by applicant): Rheumatoid arthritis (RA) is among the most common autoimmune diseases. The current treatment for RA is mainly by targeting tumor-necrosis factor (TNF). Despite the remarkable efficacy, significant portion of RA patients are not responsive to this class of drugs. Therefore, there is an urgent need to develop therapeutic that can complement existing therapeutic ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Scleroderma Subtyping from Fresh and Archived Biopsies using NextGen Sequencing

    SBC: CELDARA MEDICAL, LLC            Topic: NIAMS

    DESCRIPTION (provided by applicant): Systemic sclerosis (SSc) is an autoimmune disease that presents with a heterogeneous and complex phenotype. Major manifestations of the disease are skin fibrosis, vascular dysfunction, and immune system activation. There are no validated diagnostic markers. There are no curative treatments. One in three patients dies within 10 years of diagnosis. Some drugs (de ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Amelioration of Claustrophobia and Disruptive Patient Motion in MR Imaging

    SBC: HYPNALGESICS, LLC            Topic: NCCAM

    DESCRIPTION (provided by applicant): Claustrophobia and disruptive patient motion are common impediments to MRI examination, but they may be prevented or ameliorated with a non-pharmacologic behavioral intervention administered by trained staff. The potential benefits of such an intervention are highly significant, considering that the alternatives are to cancel the study or administer sedation. I ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Virus-Targeted Therapy for Malignancies

    SBC: Phoenicia Biosciences, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is associated with a number of human malignancies for which there are presently few effective treatments. Lymphoid malignancies caused by, or associated with, Epstein-Barr virus include Burkitt's lymphoma, T/NK lymphomas, some T- and B-cell lymphomas, approximately half of Hodgkin's lymphomas and all post-transplant lymphopro ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Rapid Testing of Drug-Resistant BCR-ABL(+)Leukemia Cells

    SBC: BIOSENSE TECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Resistance to chemotherapeutic drugs is an ongoing problem that results in eventual treatment failures or suboptimal patient outcomes. In cancer cells treated with drugs to which they are sensitive, the stress responseis the first step in the subsequent cascade leading to cell death (apoptotic, necrotic or autophagy). The recent availability of a sensing modali ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Serum GP88 biomarker as a surrogate marker for disease progression in breast canc

    SBC: A&G PHARMACEUTICAL, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): 40,000 women die annually in the US as a result of breast cancer (BC). Although BC can be controlled if detected early, a significant number is not detected until later and these patients are treated using therapies tocontrol both primary tumor and micro-metastatic disease. Therapy response is monitored using imaging and clinical assessment. Failure to detect e ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government